DEC 14, 2017 8:00 AM PST

WEBINAR: Emergence of Clinical Proteomics: Identifying and developing actionable protein biomarkers for use in clinical research.

Sponsored by: Thermo Fisher Scientific
  • President of Proteomics, NantOmics
      Todd Hembrough, PhD is the President, Proteomics at NantOmics where he oversees R&D, operations, and the clinical proteomics laboratory. Todd obtained his Ph.D. in Biochemistry from the University of Virginia, studying the role of proteinases in tumor growth and invasion. Prior to NantOmics, Todd was a leader of the translational oncology efforts at EntreMed, focusing on defining druggable molecular pathways and inventing new drugs to target these pathways. Todd later became the Chief Scientific Officer and Head of R&D at OncoPlex Diagnostics and Expression Pathology where he helped lead the development and commercial launch of the first quantitative proteomic assays performed on formalin-fixed, paraffin-embedded tissue.
    • Manager, Assay Development, NantOmics
        Maryann Vogelsang, PhD leads the assay development team, and drives the implementation and delivery of NantOmics' mass spectrometry (MS)-based assay development pipeline for both R&D and clinical proteomics laboratories. Maryann earned her PhD in Biochemistry and Molecular Biology from the University of California, Los Angeles. Prior to NantOmics, Maryann established a CLIA compliant laboratory that offered both ELISA- and MS-based clinical assays. She has over a decade of experience in translational medicine utilizing the mass spectrometry platform, and spent a significant part of her career as a scientist developing workflows that facilitate proteomics biomarker discovery and validation processes at the Thermo Fisher Scientific BRIMS Center.


      DATE: December 14, 2017
      TIME: 08:00am PST, 11:00am EST, 4:00pm BST, 5:00pm CEST

      The benefits of genomic analysis are well understood, however, the majority of patients do not harbor druggable alterations in their genomes and thus are not candidates for targeted therapies.  In patients whose tumors lack genomic biomarkers for targeted therapies or have developed resistance, clinical proteomics is identifying protein biomarkers for therapies that are benefitting patients—thus fueling the emergence of proteogenomics. 

      We have built more than 250 quantitative proteomic assays for relevant oncology biomarkers expressed in solubilized, formalin-fixed, paraffin-embedded tumor samples using selected reaction monitoring mass spectrometry.  This webinar will cover the assay development pipeline utilized to bring these quantitative proteomic markers into our CAP-CLIA laboratory.  Starting from a targeted-discovery initiative to the analytical validation of our multiplexed SRM methods, we will discuss the metrics used to validate our assays. 

      Additionally, this webinar will introduce the impact these developed markers have on clinical research, including the retrospective analyses of HER2 proteomic expression in adjuvant and metastatic breast cancer and in advanced gastric cancer.  The HER2 proteomic expression levels correlated with response to trastuzumab.  From this correlation, we were able to identify a proteomic cut-off value of response.  This potential benefit extended to donors identified as non-breast/non-gastric cancer patients who overexpressed HER2 and who subsequently responded to HER2-targeted therapy.

      Key Learning Objectives:

      • Metrics used to analytically validate a multiplexed proteomic LC-MS assay.
      • Workflows and processes used in working with Liquid Tissue®.
      • The clinical impact on delivering much needed biomarkers of therapeutic response.

      Show Resources